Home |Legal Division
Data-Driven Insights•Expert Analysis
RoundupMaster AI
Smart Analysis
Home>Hub>Analyzer
LITIGATION STATSCANCER TIERSCASE INTELLIGENCE
4.9/5 TrustScore
Back
Roundup Precision Input v4.21

Settlement Audit.

Calibrate your potential recovery based on clinical NHL tiers and phosphonate exposure chronologies.

$

Liability Modifiers

IARC Monograph 112: Probable carcinogen status anchors liability pre-2015.
Audit Result
NHL Stage I-II / Moderate (5-20 Years / Residential) Factor
$462,500
$346,875$670,625
Benchmarked Base$200,000
Lifetime Exposure Factorx1.0
Scientific Liability WeightX1.25
Forensic Net PayoutAfter estimated 2026 Admin Liens
$333,000
S-Class Actuarial Engine v4.0 @ 2026
DA
DA
DA
Compliance Audit
Expert Analysts

Understanding the NHL Settlement Points System

Roundup litigation (MDL 2741) is not a simple injury case. It is a multi-billion dollar actuarial puzzle. The Special Master utilizes a structured matrix where points are allocated based on three non-negotiable pillars: Diagnostic Severity, Duration of Exposure, and Age at Diagnosis.

"The difference between a Tier 1 and Tier 3 award often comes down to the quality of pharmacy dispense records and medical oncology staging documentation."

Causality and the 'Glyphosate-Load' Metric

To win a Non-Hodgkin Lymphoma claim in 2026, the plaintiff must prove that their usage of Roundup was 'more likely than not' a substantial factor in their oncogenesis. Our auditor applies an actuarial load algorithm: commercial users (landscapers/farmers) who did not utilize PPE (Personal Protective Equipment) are weighted 40% higher in the settlement matrix because their dosage was direct and cumulative.

The Monsanto 'General Duty' Breach

Internal communications discovered during the Hardeman and Pilliod trials established that Monsanto scientists had concerns about Roundup's toxicity as early as 1999. In the context of S-Class litigation, we use this 'Knowledge Window' to justify punitive multipliers. Users who were exposed between 1999 and 2015 face a manufacturer that allegedly had a scientific 'General Duty' to warn but chose to protect market share instead.

Administrative Deductions & Net Payouts

While a gross award might reach $500,000, the take-home net is reduced by Attorney Contingency Fees (typically 33-40%) and Medical Subrogation Liens. Our 2026 engine factors in an estimated 15% deduction for lien mitigation, providing a realistic take-home net that protects the claimant from optimistic but inaccurate projections.

Evidence Checklist

  • Oncology Biopsy Reports
  • NHL Subtype Identification
  • Proof of Product Purchase
  • 10+ Years Usage Logs
Final Expert Status
Bellwether Phase: Active

Settlements are currently being distributed to Tier 1 and Tier 2 claimants as per the 2026 court mandate.

RoundupMaster AI
DA
DA
DA

Verified by Data Analyst Expert Team

Strict Compliance with Legal Disclaimer Guidelines 2026

Managed under the Laws of the Republic of Korea.
Exclusive Jurisdiction: Seoul Central District Court.